Aug
3
Las Vegas, NV – August 03, 2015 — (TechSonian) – Varian Medical Systems, Inc. (NYSE:VAR) has been awarded an eight-year tender to supply advanced radiotherapy equipment and software to a network of hospitals in Galicia, in the northwest of Spain. Varian booked the order, worth an estimated €21m ($23m), in its fiscal third quarter.
Under the terms of the contract Varian will supply 10 linear accelerators, including three advanced TrueBeam™ systems, to five hospitals in the SERGAS network of hospitals in the Galicia region. Varian will also be installing its full suite of treatment planning software and oncology information management systems across the network.
Varian Medical Systems, Inc. (NYSE:VAR) reported the surge of +0.08% and closed at $86.07, with the total traded volume of 1.13 million shares. During last trade its minimum price was $85.70 and it gained its highest price of $87.13 and has a total of 99.80 million outstanding shares.
Can Investors Bet on VAR after this News update? Find out in this Research Report
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) declared that it will become a component of the NASDAQ-100 Index(R) (NASDAQ:NDX), the NASDAQ-100 Equal Weighted Index (NASDAQ:NDXE) and the NASDAQ-100 Ex-Technology Index (NASDAQ:NDXX) prior to market open on Monday, July 27, 2015. The NASDAQ-100 Index is composed of the 100 largest non-financial stocks listed on The NASDAQ Stock Market based on market capitalization.
“We are proud to become a member of such a prestigious group and be recognized as one of the 100 most valuable companies on the NASDAQ,” stated Jean-Jacques Bienaime, Chairman and Chief Executive Officer of BioMarin. “Since our founding we have demonstrated our unique ability to develop medicines for patients born with extremely rare diseases who have few or no treatment options. We are honored that our innovative and cutting edge therapies have led to this important recognition.”
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) showing jumped of +1.18% and closed at $146.27, after gaining total volume of 1.12 million shares. Its earnings per share (EPS) is -$1.08 and its beta value stands at 0.65 points and has total market capitalization of $23.45 billion and a total of 160.34 million outstanding shares.
Is BMRN a Solid Investment at These Levels? Read This Report For Details
Quest Diagnostics Inc (NYSE:DGX) declared a nationwide campaign to improve understanding of the advantages, limitations and clinically appropriate interpretation of results of noninvasive prenatal screening and other diagnostic tests for pregnant women and their healthcare providers. Quest Diagnostics (DGX), the world’s leading provider of diagnostic information services, is the first commercial organization to support the initiative, through a grant.
Quest Diagnostics Inc (NYSE:DGX) increased +0.44% closed at $73.81 and traded with total volume of 1.10 million shares, while the average trading remained 1.12 million shares. During last trade its minimum price was $73.65 and it gained the highest price of $74.49. Its market capitalization was $10.60 billion.
How Should Investors Trade DGX Now? Don’t Miss out a Special Trend Analysis
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) declared that it will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Wednesday, August 5, 2015, to discuss second quarter 2015 financial results and provide a corporate update. Arena will release its financial results after the NASDAQ Global Select Market closes that day.
The conference call may be accessed by dialing 877.643.7155 for domestic callers and 914.495.8552 for international callers. Please specify to the operator that you would like to join the “Arena Pharmaceuticals’ Second Quarter 2015 Financial Results and Corporate Update Conference Call.” The conference call will be webcast live under the investor relations section of Arena’s website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported the surge of +1.76%, after closing price for the day was $4.04. Its total trading volume for the day was 1.12 million shares, versus its average volume of 2.68 million shares. Its earnings per share are -$0.26.
What ARNA Charts Are Signaling for Traders? Find Out Here
Open all references in tabs: [1 – 5]
Comments
Leave a Reply
You must be logged in to post a comment.